In non-small cell lung cancers (NSCLC), mutations in NF1, MET, and ERBB2 account for up to 13% of tumors analyzed by molecular profiling, and elevation in MAPK and PI3K activity was observed in a large proportion of cases [15]. Here, NF1 is linked to non-small cell lung carcinoma.